Administration of Bcl-2 antagonist, sabutoclax, concurrently suppresses IL-6/STAT3 signaling to resensitize chemoresistant breast cancer cells to chemotherapeutic agents (175). The gene discussed is IL6; the disease is breast carcinoma.